OncoMatch/Clinical Trials/NCT05412290
Mosunetuzumab Consolidation Therapy After autoSCT in r/r Aggressive B Cell Lymphoma
Is NCT05412290 recruiting? Yes, currently enrolling (May 2026). This Phase 1 trial studies Mosunetuzumab for b cell lymphoma.
Treatment: Mosunetuzumab — This phase 1 pilot study examines the feasibility and safety of mosunetuzumab after autologous stem cell transplant for patients with aggressive B cell lymphomas. Mosunetuzumab is an antibody that has been engineered to attach to two target cells in the immune system: T cells that normally perform tasks like killing virus-infected cells, and cancerous B cells. Mosunetuzumab has been designed to direct these T cells to kill the cancerous B cells instead.
Check if I qualifyExtracted eligibility criteria
Cancer type
Non-Hodgkin Lymphoma
Diffuse Large B-Cell Lymphoma
Biomarker criteria
Required: CD20 positive
Diagnosis of rCD20+ large B cell lymphoma
Performance status
ECOG 0–2(Ambulatory, capable of self-care)
Prior therapy
Must have received: cytotoxic chemotherapy
two or more prior lines of therapy for lymphoma, including treatment for prior/underlying indolent B-NHL
Cannot have received: allogeneic stem cell transplant
Prior allogeneic stem cell transplant
Cannot have received: solid organ transplantation
History of solid organ transplantation
Lab requirements
Blood counts
Absolute neutrophil count ≥ 1,000/mcL without G-CSF use in past 7 days; Platelets ≥ 75,000/mcL without TPO mimetic use in past 7 days; Hemoglobin ≥ 8 g/dL without red blood cell transfusion in past 7 days
Kidney function
Measured or estimated creatinine clearance ≥ 50 mL/min by Cockcroft-Gault
Liver function
Serum total bilirubin ≤ 1.5 x IULN (or ≤ 3 x IULN for patients with Gilbert syndrome); AST(SGOT)/ALT(SGPT) ≤ 2.5 x IULN
Adequate hematologic function defined as follows: Absolute neutrophil count ≥ 1,000/mcL without G-CSF use in past 7 days; Platelets ≥ 75,000/mcL without TPO mimetic use in past 7 days; Hemoglobin ≥ 8 g/dL without red blood cell transfusion in past 7 days. Normal laboratory values: Serum total bilirubin ≤ 1.5 x IULN (or ≤ 3 x IULN for patients with Gilbert syndrome); AST(SGOT)/ALT(SGPT) ≤ 2.5 x IULN; Measured or estimated creatinine clearance ≥ 50 mL/min by Cockcroft-Gault
Structured fields extracted by AI. May contain errors — verify against the official protocol.
US trial sites
- Washington University School of Medicine · St Louis, Missouri
Showing up to 5 US sites. See all sites on ClinicalTrials.gov →
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify